{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:55:02Z","timestamp":1768254902584,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005909","name":"University of California Institute for Mexico and the United States","doi-asserted-by":"publisher","award":["T32AI106704"],"award-info":[{"award-number":["T32AI106704"]}],"id":[{"id":"10.13039\/100005909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["62288"],"award-info":[{"award-number":["62288"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021369","name":"OCRA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AI106704"],"award-info":[{"award-number":["T32AI106704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020400","name":"Clinical and Translational Science Center, Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027260","name":"Delta Dental of Colorado Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000925","name":"John Templeton Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007760","name":"College of Medicine Office of Research, Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008523","name":"Center for Clinical and Translational Science, University of Illinois at Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008523","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.soc.2024.12.004","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T07:22:05Z","timestamp":1736148125000},"page":"265-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperthermic Intraperitoneal Chemotherapy in the Management of Ovarian, Fallopian Tube and Peritoneal Carcinomas"],"prefix":"10.1016","volume":"34","author":[{"given":"Julia","family":"Chalif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floor","family":"Backes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2024.12.004_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.soc.2024.12.004_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.soc.2024.12.004_bib3","unstructured":"Cancer Statistics Explorer Network. National cancer Institute surveillance, epidemiology, and end results program. 2024. Accessed June 24, 2024."},{"issue":"1","key":"10.1016\/j.soc.2024.12.004_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0039-6109(16)41440-4","article-title":"Intensive surgical and chemotherapeutic management of advanced ovarian cancer","volume":"58","author":"Griffiths","year":"1978","journal-title":"Surg Clin North Am"},{"issue":"9","key":"10.1016\/j.soc.2024.12.004_bib5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN Guidelines\u00ae insights: ovarian cancer, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Armstrong","year":"2022","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"10177","key":"10.1016\/j.soc.2024.12.004_bib6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.soc.2024.12.004_bib7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.soc.2024.12.004_bib8","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2024.12.004_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in The Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.soc.2024.12.004_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib11","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: what is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland Surg"},{"issue":"1","key":"10.1016\/j.soc.2024.12.004_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.soc.2024.12.004_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.soc.2024.12.004_bib14","first-page":"1460","article-title":"Long-Term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J\u00a0Clin Orthod"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.12.004_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.soc.2024.12.004_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.004_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2024.12.004_bib19","doi-asserted-by":"crossref","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.soc.2024.12.004_bib20","doi-asserted-by":"crossref","first-page":"8115","DOI":"10.1245\/s10434-023-13932-3","article-title":"The 2022 PSOGI international Consensus on HIPEC regimens for peritoneal malignancies: epithelial ovarian cancer","volume":"30","author":"Bhatt","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2024.12.004_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.addr.2020.07.007","article-title":"Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy","volume":"163-164","author":"Dunne","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"17","key":"10.1016\/j.soc.2024.12.004_bib22","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.3390\/ijms231710078","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC): an overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers","volume":"23","author":"Lim","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.soc.2024.12.004_bib23","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/cancers15051402","article-title":"Mechanistic insights on hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"15","author":"Huffman","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/antiox11040625","article-title":"Hyperthermia treatment as a promising anti-cancer strategy: therapeutic targets, perspective mechanisms and synergistic combinations in experimental approaches","volume":"11","author":"Yi","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10.1016\/j.soc.2024.12.004_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"de Bree","year":"2017","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"10.1016\/j.soc.2024.12.004_bib26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","article-title":"Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines","volume":"34","author":"van de Vaart","year":"1998","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3892\/or.2021.7974","article-title":"Direct and indirect anticancer effects of hyperthermic intraperitoneal chemotherapy on peritoneal malignancies (Review)","volume":"45","author":"Zhang","year":"2021","journal-title":"Oncol Rep"},{"issue":"8","key":"10.1016\/j.soc.2024.12.004_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.21037\/atm-22-955","article-title":"Hyperthermia enhances the efficacy of chemotherapeutic drugs in heat-sensitive cells through interfering with DNA damage repair","volume":"10","author":"Ni","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.soc.2024.12.004_bib29","first-page":"9","article-title":"Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"4","author":"Muenyi","year":"2011","journal-title":"J\u00a0Ovarian Res"},{"issue":"Suppl 3","key":"10.1016\/j.soc.2024.12.004_bib30","doi-asserted-by":"crossref","first-page":"S588","DOI":"10.1245\/s10434-015-4580-6","article-title":"Histologic and immunohistochemical alterations associated with cytoreductive surgery and heated intraperitoneal chemotherapy","volume":"22","author":"Wagner","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.soc.2024.12.004_bib31","doi-asserted-by":"crossref","first-page":"8868","DOI":"10.3390\/ijms24108868","article-title":"DNA repair pathway in ovarian cancer patients treated with HIPEC","volume":"24","author":"Flasarova","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.soc.2024.12.004_bib32","doi-asserted-by":"crossref","first-page":"9851","DOI":"10.1073\/pnas.1101053108","article-title":"Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition","volume":"108","author":"Krawczyk","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.soc.2024.12.004_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1471-4906(01)02168-8","article-title":"Heat-shock proteins as activators of the innate immune system","volume":"23","author":"Wallin","year":"2002","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.004_bib34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41388-019-1016-y","article-title":"Heat-shock proteins: chaperoning DNA repair","volume":"39","author":"Dubrez","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.soc.2024.12.004_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nri3843","article-title":"Fever and the thermal regulation of immunity: the immune system feels the heat","volume":"15","author":"Evans","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.004_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/02656736.2012.677933","article-title":"Old and new facts about hyperthermia-induced modulations of the immune system","volume":"28","author":"Frey","year":"2012","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"10.1016\/j.soc.2024.12.004_bib37","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","article-title":"A\u00a0guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology","volume":"158","author":"Chambers","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.soc.2012.07.013","article-title":"Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy","volume":"21","author":"Van der Speeten","year":"2012","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib39","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2024.12.004_bib40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.soc.2024.12.004_bib41","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.004_bib42","doi-asserted-by":"crossref","first-page":"102052","DOI":"10.1016\/j.esmoop.2023.102052","article-title":"Surgery and HIPEC in relapse for all patients with ovarian cancer?","volume":"8","author":"Hasson","year":"2023","journal-title":"ESMO Open"},{"issue":"Suppl 3","key":"10.1016\/j.soc.2024.12.004_bib43","article-title":"#876 Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the chipor randomised phase III trial","volume":"33","author":"Classe","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.soc.2024.12.004_bib44","doi-asserted-by":"crossref","first-page":"100796","DOI":"10.1016\/j.gore.2021.100796","article-title":"The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer","volume":"37","author":"Glennon","year":"2021","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"10.1016\/j.soc.2024.12.004_bib45","doi-asserted-by":"crossref","first-page":"107955","DOI":"10.1016\/j.ejso.2024.107955","article-title":"Eliminating the need for preoperative intravenous hyperhydration: sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients - a retrospective analysis","volume":"50","author":"Vachez","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.004_bib46","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2021.01.006","article-title":"Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer","volume":"161","author":"Chichura","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.soc.2024.12.004_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ygyno.2020.09.052","article-title":"Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer","volume":"160","author":"Morton","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.soc.2024.12.004_bib48","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3802\/jgo.2019.30.e59","article-title":"Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study","volume":"30","author":"Petrillo","year":"2019","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.soc.2024.12.004_bib49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ijgc-2021-002622","article-title":"Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry","volume":"31","author":"Chambers","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.soc.2024.12.004_bib50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2021.05.013","article-title":"Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"162","author":"Chambers","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.soc.2024.12.004_bib51","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ijc.34124","article-title":"Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial","volume":"151","author":"Koole","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.soc.2024.12.004_bib52","first-page":"100518","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference?","volume":"31","author":"Ghirardi","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.soc.2024.12.004_bib53","doi-asserted-by":"crossref","first-page":"e2100239","DOI":"10.1200\/PO.21.00239","article-title":"Hyperthermic intraperitoneal chemotherapy-induced molecular changes in humans validate preclinical data in ovarian cancer","volume":"6","author":"Dellinger","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"13","key":"10.1016\/j.soc.2024.12.004_bib54","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1245\/s10434-023-13981-8","article-title":"ASO author reflections: which HIPEC regimens should be used in patients with epithelial ovarian cancer? In the clinic and in randomized trials","volume":"30","author":"Bhatt","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2024.12.004_bib55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","article-title":"Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis","volume":"167","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.soc.2024.12.004_bib56","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"16_suppl","key":"10.1016\/j.soc.2024.12.004_bib58","first-page":"TPS5638","volume":"42","author":"Backes","year":"2024","journal-title":"J\u00a0Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.soc.2024.12.004_bib60","first-page":"TPS5636","article-title":"Rationale and study design of the KOV-HIPEC-04: a phase III randomized controlled trial in primary stage III and IV ovarian cancer after interval cytoreductive surgery (FOCUS)","volume":"42","author":"Lim","year":"2024","journal-title":"J\u00a0Clin Orthod"},{"issue":"2","key":"10.1016\/j.soc.2024.12.004_bib61","doi-asserted-by":"crossref","first-page":"100098","DOI":"10.1016\/j.esmoop.2021.100098","article-title":"Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery","volume":"6","author":"El Hajj","year":"2021","journal-title":"ESMO Open"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320724000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:38:37Z","timestamp":1762360717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320724000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1055320724000905"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2024.12.004","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperthermic Intraperitoneal Chemotherapy in the Management of Ovarian, Fallopian Tube and Peritoneal Carcinomas","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2024.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}